Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From barriers to solutions: a qualitative study of access to HIV and TB care for forced migrants from Ukraine.

BMC health services research·2026
Same author

Facing disabilities in children with prenatal alcohol exposure: parenthood and stressors according to families and professionals' narratives.

Frontiers in sociology·2025
Same author

Serial neonaticide: Analysis of 126 cases.

Medicine, science, and the law·2024
Same author

Sante publique (Vandoeuvre-les-Nancy, France)·2022
Same author

[Tabacco, alcohol and pemba consumption during pregnancy in French Guyana].

Sante publique (Vandoeuvre-les-Nancy, France)·2020
Same author

Warning about drinking during pregnancy: lessons from the French experience.

Reproductive health·2018

Related Experiment Video

Updated: Jun 27, 2026

Intravascular Delivery of Biologics to the Rat Kidney
07:29

Intravascular Delivery of Biologics to the Rat Kidney

Published on: September 1, 2016

Pregnancy under high-dose buprenorphine.

Laurence Simmat-Durand1, Claude Lejeune, Laurent Gourarier

  • 1CESAMES (Université Paris Descartes- CNRS UMR 8136-INSERM U611), 45, rue des Saints-Pères, 75006 Paris, France. laurence.simmat-durand@parisdescartes.fr

European Journal of Obstetrics, Gynecology, and Reproductive Biology
|December 9, 2008
PubMed
Summary

High-dose buprenorphine in pregnancy did not correlate with neonatal abstinence syndrome severity. Maternal compliance with addiction treatment was the primary factor influencing neonatal outcomes in women using opioid substitution therapy.

More Related Videos

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

Related Experiment Videos

Last Updated: Jun 27, 2026

Intravascular Delivery of Biologics to the Rat Kidney
07:29

Intravascular Delivery of Biologics to the Rat Kidney

Published on: September 1, 2016

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

Area of Science:

  • Obstetrics and Gynecology
  • Addiction Medicine
  • Neonatal Care

Background:

  • Opioid substitution therapy (OST) during pregnancy, using methadone or buprenorphine, is a critical intervention for maternal and fetal health.
  • Understanding the characteristics of women receiving high-dose buprenorphine (HDB) and their impact on neonatal outcomes is essential for optimizing care.
  • Heterogeneity exists within populations of pregnant women undergoing OST, necessitating detailed characterization.

Purpose of the Study:

  • To describe the heterogeneity of women receiving high-dose buprenorphine (HDB) during pregnancy in France.
  • To analyze the characteristics of women undergoing HDB treatment, including social factors and drug use patterns.
  • To investigate the relationship between maternal characteristics, treatment, and neonatal abstinence syndrome (NAS).

Main Methods:

  • Retrospective analysis of data from 159 women receiving HDB during pregnancy and their 160 newborns.
  • Data collection encompassed pregnancy, delivery outcomes, and neonatal parameters from 35 French hospitals and clinics (October 1998 - September 1999).
  • Women were categorized based on social disadvantage, and characteristics like smoking, heroin use, and HDB injection were recorded.

Main Results:

  • Two distinct populations of women were identified: 64 without social disadvantage and 95 with social disadvantage.
  • A significant proportion (43%) belonged to a 'hidden population' of drug users, often native French citizens treated by general practitioners.
  • Neonatal abstinence syndrome (NAS) severity and duration were not correlated with HDB dosage but were linked to maternal compliance with addiction treatment.

Conclusions:

  • Maternal compliance with addiction treatment programs is the key determinant of neonatal abstinence syndrome severity in women on HDB.
  • Socially disadvantaged and non-disadvantaged women on HDB did not differ in NAS severity, highlighting the importance of adherence.
  • The study underscores the need for comprehensive support and monitoring for all pregnant women undergoing opioid substitution therapy.